A Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00986219
First received: September 22, 2009
Last updated: December 16, 2009
Last verified: December 2009
  Purpose

The purpose of the study is to evaluate the concordance of the most frequently used words by the patients and the physicians to express asthma symptoms and the limitations of daily activities caused by asthma.


Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: A Cross Sectional Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms and the Limitations of Daily Activities in Primary Care. The " Asthma Language " Survey

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The concordance of the most frequently used words by the patients and the physicians to express asthma symptoms and the limitations of daily activities caused by asthma [ Time Frame: Day 1 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The most frequently used words (lexical intensity) by the patient and the physician to express asthma symptoms and the limitations of daily activities. [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • The concordance of words used by physicians and patients according to the level of asthma control (as assessed by ACQ). [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • The actions recommended by the physician or those initiated by the patient and are associated with words that express symptoms. [ Time Frame: Day 1 ] [ Designated as safety issue: No ]

Enrollment: 696
Study Start Date: September 2009
Study Completion Date: December 2009
Groups/Cohorts
Asthma Language between patients and physicians

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Primary care patients with persistent asthma treated with inhaled corticosteroid-based maintenance treatment for at least 6 months and followed up by thep hysician for at least the same period of time.

Criteria

Inclusion Criteria:

  • Diagnosis of persistent asthma treated with inhaled corticosteroid-based maintenance treatment for at least 6 months and followed up by the investigator for at least the same period of time

Exclusion Criteria:

  • Patient with a cardiac disease (congestive heart failure, coronary heart disease)
  • Patient with a respiratory disease other than asthma (COPD, sleep apnoea syndrome)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00986219

Locations
Greece
Research Site
Patras, Achaia, Greece
Research Site
Agrinio, Aitoloakarnanias, Greece
Research Site
Thermo, Aitoloakarnanias, Greece
Research Site
Naupaktos, Aitoloakarnania, Greece
Research Site
Argos, Argolida, Greece
Research Site
Arta, Artas, Greece
Research Site
Athens, Attiki, Greece
Research Site
Peraious, Attiki, Greece
Research Site
Livadia, Biotias, Greece
Research Site
Chania, Crete, Greece
Research Site
Herakleion, Crete, Greece
Research Site
Rethimno, Crete, Greece
Research Site
Siros, Cyclades, Greece
Research Site
Rodos, Dodekanisou, Greece
Research Site
Drama, Drammas, Greece
Research Site
Kastoria, Florinas, Greece
Research Site
Amfisa, Fokidos, Greece
Research Site
Pirgos, Ilia, Greece
Research Site
Veroia, Imathia, Greece
Research Site
Ioannina, Ioanninon, Greece
Research Site
Karditsa, Karditsis, Greece
Research Site
Chrisoupoli, Kavalas, Greece
Research Site
Kavala, Kavalas, Greece
Research Site
Loutraki, Korinthia, Greece
Research Site
Ptolemaida, Kozani, Greece
Research Site
Ksanthi, Ksanthis, Greece
Research Site
Larisa, Larisas, Greece
Research Site
Farsala, Larrisa, Greece
Research Site
Volos, Magnisia, Greece
Research Site
Kalamata, Messinia, Greece
Research Site
Aikaterini, Peierias, Greece
Research Site
Edessa, Pella, Greece
Research Site
Komotini, Rodopi, Greece
Research Site
Serres, Serron, Greece
Research Site
Igoumenitsa, Thesprotia, Greece
Research Site
Salonika, Thessalonikis, Greece
Research Site
Trikala, Trikalon, Greece
Research Site
Chalkida, Greece
Research Site
Chalkidiki, Greece
Research Site
Lakonia, Greece
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Mina Gaga, MD Director of the 7th Respiratory Clinic, Sotiria Hospital, Athens, Greece
Study Director: Panagiotis Pontikis, Dr. Marketing Company Medical Director, AstraZeneca Greece
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00986219     History of Changes
Other Study ID Numbers: NIS-RGR-DUM-2009/1
Study First Received: September 22, 2009
Last Updated: December 16, 2009
Health Authority: Greece: National Organization of Medicines

Keywords provided by AstraZeneca:
Asthma
Language
Symptoms,
Limitation of Daily activities
Patients
Physicians
Greece

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on August 21, 2014